Introducing a Single-Agent, Abuse-Deterrent, Extended-Release Morphine
This presentation will shine a light on the growing public health issue of prescription opioid abuse and introduce the audience to a single-agent, abuse-deterrent, extended-release morphine product. An expert faculty will take the audience through an in-depth look into the product, the 3 categories of evidence supporting its expected abuse-deterrent properties, and important safety and dosing information. The audience will also have the opportunity to ask questions to gain a deep understanding of the product.
- Understand the role of an abuse-deterrent, extended-release morphine in helping to fight prescription opioid abuse
- Understand the various categories of evidence recommended to support an abuse-deterrent formulation per FDA industry guidance
- Learn about a single-agent, abuse-deterrent morphine that retains extended-release properties even if manipulated and that is expected to reduce abuse via intranasal and intravenous routes. However, abuse by intranasal, intravenous, and oral routes is still possible
- Gain deep understanding of the technology and the differentiating abuse-deterrent properties of the product
- Gain familiarity with the important prescribing considerations and Important Safety Information of the product
AAPM provided breakfast.
Activity funded by Daiichi Sankyo, Inc. & Inspirion Delivery Sciences
Jeffrey Gudin, MD